hrp0097p1-90 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023
Yi-Lin Ng Amy
, Agarwal Pankaj
, Vijayan Roopa
, B Arya Ved
, R Kapoor Ritika
, Shah Pratik
Background: Diazoxide therapy is used as first line treatment in hyperinsulinaemic hypoglycaemia (HH). Apart from a single study reporting efficacy of low dose diazoxide in small for gestational age (SGA) infants, diazoxide has been reported to be used in doses of 5-20 mg/kg/day [1].Objective: To report the outcomes of infants with HH responsive to low dose diazoxide (≤5mg/kg/day).Method...